The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development ...
Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced ...
LONDON--(BUSINESS WIRE)--The Pharmaceutical Formulation Equipment market will register an incremental spend of about USD 7.35 billion, growing at a CAGR of 8.42% during the five-year forecast period.
LONDON--(BUSINESS WIRE)--Global procurement intelligence advisory firm, SpendEdge, has announced the release of their ‘Pharmaceutical Formulation Equipment Procurement Research Report.’ The insights ...
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for TRN-257, a controlled-release, low-sodium oxybate product, for the treatment of cataplexy or excessive ...
MELBOURNE, Australia, Sept. 28, 2025 (GLOBE NEWSWIRE) -- CLINUVEL today announced that it is advancing new sustained-release liquid drug formulations in a preclinical program evaluating various drug ...
Researchers at the University of Toronto say they have successfully tested the use of machine learning models to guide the design of long-acting injectable drug formulations. The potential for machine ...
This article previews some formulation topics discussed in the Pharma Fundamentals series, which aims to enhance learning for professionals in pharmaceutical drug development and manufacturing. It is ...
VANCOUVER, BC / ACCESS Newswire / December 1, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
Pharmacy is the drug developer, overseeing clinical studies and formulation. Check the NIRF 2025 ranking of the best pharmacy ...
In a dramatic change to Australian patent law, Australia's Full Federal Court has just held that patents for pharmaceutical formulations are not eligible for patent term extensions ( PTE ): Otsuka ...
BioCryst secures FDA approval for Orladeyo oral pellets, expanding preventive HAE therapy to children ages 2 to under 12.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback